These results are comparable to patients with CF with a Gly551Asp mutation treated with ivacaftor monotherapy, resulting in improvements of 52% of normal CFTR activity in ICM studies (Graeber et al., 2015). This evidence concerns the gene CFTR and cystic fibrosis.